Rethinking child treatments

Developing evidence-based treatments - specifically for children

Releases

Releases

11. February, 2021

Year-end report Q4-2020 – on track and accelerating clinical activities

Cessatech A/S today releases its results for the period 6. April – 31 December 2020. The company is on track with Q4 activities and getting...

Read more

Releases

21. January, 2021

Supporting ‘Save the Children’

Cessatech has entered a corporate sponsorship with Save the Children. We want to make...

Read more

Releases

27. November, 2020

Cessatech’s IPO of units significantly oversubscribed

Subscribed to DKK 107 million, corresponding to a subscription ratio of approx. 680 percent....

Read more

Releases

6. November, 2020

Approval for IPO listing

Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application...

Read more

Releases

18. August, 2020

Strong profiles to the Board

The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations

Read more

Facts about Children

Facts

2. February, 2021

Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner

Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...

Read more

Facts

31. August, 2020

DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem

Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...

Read more

Facts

5. June, 2020

High off-label use in Children

Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label...

Read more

Facts

1. May, 2020

Children are not small adults

Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses

Read more

Experience

Proven track-record within drug development and product launches, in Europe, US and Asia.

The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.

Team
Lead Asset

CT001 – Nasal spray

Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.

See details

Stay up to date!

Subscribe and get notified on Cessatech's latest news.